Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Cluster Headache * Diagnosis of patients with CH shall be in accordance with The International Classification of Headache Disorders, 2nd Edition: A. At least 5 attacks fulfilling B-D B. Severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 15-180 minutes if untreated C. Headache is accompanied by at least 1 of the following: 1. ipsilateral conjunctival injection and/or lacrimation 2. ipsilateral nasal congestion and/or rhinorrhoea 3. ipsilateral eyelid oedema 4. ipsilateral forehead and facial sweating 5. ipsilateral miosis and/or ptosis 6. a sense of restlessness or agitation D. Attacks have a frequency from 1 every other day to 8 per day E. Not attributed to another disorder Chronic cluster headache A. Attacks fulfilling A-E for Cluster headache B. Attacks recur over >1 year without remission periods or with remission periods lasting <1 month ICHD-II for CCH (see above) Minimum mean attack frequency of 4 attacks per week Minimum age of 18 years old Signed study specific informed consent form Agreeing to refrain from starting new prophylactic CH medication, including steroids, or any other therapy aimed at CH and agrees to maintain existing prophylactic CH medication from 4 weeks before entering the baseline period throughout the duration of the double blind phase of the study. It is allowed to change the dose of prophylactic medication during the study based on the opinion of the treating medical specialist Availability during follow-up period An MRI to structural lesions potentially causing CCH Medically intractable (see below) Definition medically intractable : Failed adequate trials of regulatory approved and conventional treatments according to local national guidelines Adequate trial: Appropriate dose and duration of treatment according to local guidelines Appropriate length of time Consideration of medication overuse Failed: No therapeutic or unsatisfactory effect, intolerable side effects, contraindications to use Must have tried agents of at least three classes of the following, of which 1 and 2 are obligatory, and 1 should come from 3-5: (recommendation of Goadsby et al. applied to Dutch national guidelines) 1. Verapamil 2. Lithium 3. Methysergide 4. Topiramate 5. Gabapentin  Other significant neurological or disabling diseases which in the opinion of the clinician may interfere with the study Pregnancy or the wish to become pregnant during the study period Cardiac pacemaker and other neuromodulatory devices Psychiatric or cognitive disorders and/or behavioural problems which in the opinion of the clinician may interfere with the study Taking CH prophylactic medication for conditions other than CH which in the opinion of the clinician may interfere with the study Serious drug habituation and/or overuse of acute headache medication for other headaches than CH Inability to complete the (electronic) diary in a sensible and accurate manner Structural intracranial or cervical vascular lesions that may potentially cause CH Previous destructive surgery involving the C2 or C3 roots (vertebrae) or deep brain stimulation Enrollment in other clinical studies that may confound the results of this study